Abstract P169: Intensive Nutrigenomic-based Dietary and Supplement Management of Coronary Artery Disease Utilizing Quarterly Measured Advanced Cardiovascular and Genetic Risk Markers: Ten Year Followup
Introduction: Coronary Artery Disease (CAD) is thought to be progressive; standard treatment protocols call for instituting/instructing a low fat/low cholesterol diet program, exercise, and lipid lowering agents in an effort to slow the onset of recurrent MI’s, stents, CABG’s, stroke, or death. This results in an approximate 30-40% new event rate in 5 yrs.
Methods: Based upon our initial experience using a Nutrigenomic-based diet to prevent/reverse Metabolic Syndrome and CAD, we have enrolled and followed 925 pts (aged 42-89 yrs) with known CAD, defined as previous MI, stent, CABG, or positive stress test/angiogram, into a diet and supplement based, physician coached, program. The diet consisted of avoidance of white or beige foods (refined and/or ground whole grains) ½ cup of raw nuts/day and large amounts of leafy green vegetables with very limited access to fruits/juices. Supplements were individualized based on results of Advanced Cardiovascular Risk Markers, which were sent to a core lab, (Berkeley Heart Labs, Alameda, CA) every three months and followed to measure compliance and to institute changes in Nutrigenomic-based supplement/eating regimens.
Results: Pts have been followed for 1.5 to 10 years (mean 8 yrs). While enrolled, only 6/925 pts (0.6%) have received a new stent, two that were predicted by a rising Lp-PLA2, despite an HDL’s of 110-120 mg/dl. There have been no MI’s, CABG’s, unstable angina, or deaths. One pt underwent carotid endarterectomy for known carotid stenosis; one pt suffered a CVA while in atrial fibrillation. Total CV events over 5 years is 8/925 (0.9%)
Conclusions: We conclude that simple Nutrigenomic-based dietary interventions, with compliance and supplement choices based upon every three month assessment of advanced cardiovascular risk and genetic markers, represents a quantum leap forward in preventing/modifying Cardiovascular events in known CAD patients.
- © 2013 by American Heart Association, Inc.